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Poster Session I S221However, the currently used assays (e.g. total nucleated cells,
CD341 cells, and viability) do not measure functionality. Enumer-
ation of CFU-GM is generally considered to be the best functional
assay, although intra-laboratory variation is high. In addition,
CFU-GM measured post cryopreservation are often considerably
lower that pre-cryopreservation values. We hypothesized that cryo-
preserved cord blood stem cells would take longer to recover and
grow, so we compared pre-cryo CFU-GM with post-cryo CFU-
GM measured after 14, 16, 19 and 21 days in culture on 20 cord
blood units. The mean 6 SEM CFU-GM of the fresh cord blood
units was 35 6 4.3  105, with 100% viability by trypan blue. The
CBU were stored at -195oC for 4-10 weeks. The mean TNC recov-
ery was 95 613% and viability was 95 6 4%. CFU-GM results on
day 14 and 16 of the frozen samples 26% and 17% lower than the
fresh cultures (p5 0.009 and 0.03 respectively). However, the results
on day 19 (35 6 4  105) were equivalent to the fresh (pNS). These
data suggest that equivalent pre- and post cryopreservation CFU re-
sults can be obtained by allowing the latter more time to recover.183
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Cryopreservation of peripheral blood hematopoietic stem cells
(PBHSC) occurs frequently in the setting of autologous stem cell
transplantation. The long-term viability of these cells is an important
issue as these patients may eventually experience disease relapse.
Previous reports have demonstrated that cryopreserved PBHSCs
can retain viability for up to 15 years. We describe the effects of
long-term cryopreservation on progenitor viability and activity at
our institution.
A total of 60 unique PBHSC sample aliquots were evaluated after
controlled rate freezing to -90 degrees C. Ten samples were evalu-
ated for viability and activity less than 24 hours after freezing, ten
sample were evaluated after 7 years of cryopreservation, thirty-
five samples after ten years of cryopreservation, and five samples
after 11 years of cryopreservation. Following culture, product
activity was evaluated by microscopy for colony forming unit
granulocyte-macrophage- (CFU-GM) and burst forming unit-
erythrocyte- (BFU-E) colonies. Sample viability was measure by
trypan blue assay.
Table 1 summarizes the pre- and post-freezing activity and viabil-
ity for the four groups. We noted significant differences in BFU-E/
kg activity in the controlled rate freezing group (t-test, 95% CI, p5
0.035), the BFU-E/kg activity in the 7-year samples (t-test, 95% CI,
p5 0.05), the BFU-E/kg activity in the 10-year samples (t-test, 95%
CI, p5 3*10-5), and the BFU-E/kg and CFU-GM/kg activity in the
11-year samples (t-test, 95% CI, p 5 0.032 and 0.038, respectively).
There was no significant decrease in the viability of the samples in
any of the groups.
Our series demonstrates that long-term freezing of PBHSCs and
BMHSCs does not result in a significant decrease in viability of sam-
ples but there is a significant negative effect on BFU-E activity at all
time points and CFU-GM activity after 11 years. We note a large
variability between samples and laboratories (see Table 1). Other
groups have described stable viability, but reported heterogeneityTable 1. Effect of Cryopreservation on PBHSC Activity and Viabilit
Columns 2, 3, 4:
CFU*104/kg BFU*104/kg
Controlled Rate Freezing Group (N510) (1) 44.04, 30.48 97.63, 57.7
Cryopreserved Samples, 7 years (N510) (1) 104.74, 91.24 181.19, 103.84
Cryopreserved Samples, 10 years (N535) (1) 56.35, 49.05 112.115, 59.41
Cryopreserved Samples, 11 years (N55) (2) 6.49, 2.01 13.42, 5.2
(1) Samples processed at Scripps Green Stem Cell Processing Lab, La Jolla, CAamong CFU-GM and BFU-E activity over time. This may be due
to technical skill andmethod of assay (culture versus flow cytometry).
No series has resulted in worse clinical outcomes using cryopre-
served product. Use of cryopreserved PBHSCs is an option for se-
lected patients but clinicians should consider collecting more cells
than required at the time of harvest and determining the viability
and activity of cryopreserved PBHSCs prior to transplantation.HEMATOPOIESIS/MESENCHYMAL CELLS
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Introduction: For numerous malignant and non-malignant hema-
tological diseases allogeneic hematopoietic stem cell transplantation
(HSCT) is the only curative therapy.However, a major complication
is the acute graft versus host disease (aGVHD), which is life-threat-
ening and substantially reduces efficacy of HSCT. The outcome for
patients with severe steroid-resistant aGVHD is very poor. There-
fore, it remains important to search for new therapeutic strategies
for the treatment of aGVHD.
Objective: Feasibility of the generation mesenchymal stroma cells
(MSCs) expanded with human plasma and platelet lysate (hPPL)
was tested as well as the feasibility and safety of the application of
MSCs in patients with steroid-refractory extensive aGVHD.
Method: In an open-label, non-randomized prospective phase I/II
study MSCs were extracted from the bone marrow of healthy volun-
teers, expanded with human plasma and platelet lysate (hPPL), and
stored. The patients were treated with 2x106/kg MSC. Response
rate, transplantation-related deaths, and other adverse events were
assessed for up to 12 months after the last infusion of the cells.
Results: Between January 2009 and July 2010, 16 patients were
treated; median age 31.6 years (range1.02-60.8). Organ involvement
of the aGVHD was 69% skin, 94% gastro-intestinal and 25% liver.
Overall grade was II for 5 (31%), III for 10 (63%), and IV for 1 (6%)
patients. 3 patients received 1 dose, 3 patients received 2 doses, all
other patients received 3 doses. No patient had side-effects during
or immediately after infusions of the MSC. Median follow-up was
188 days (3-643). An objective clinical response was observed in
93% of the patients. CRwas observed in 68% patients after a median
of 57 days (37-146). One third of the patients with gut aGVHD re-
lapsed (median 140 days after first MSC gift (84-210)). However,
GVHD of the gut was then sensitive for the treatment with steroids.
Overall, 7 patients died. 3 patients had recurrent malignant disease in
the first month after treatment, 2 patients due to progression of
aGVHD after reaching a partial remission, 1 patient due to abdom-
inal bleeding and 1 due to unknown cause.
Conclusion: Generation and infusion of MSCs in steroid-resistant
aGVHDgrade II- IV is a feasible, safe and very effective. In addition,
also patients who initially responded toMSCs but develop later a re-
lapse of aGVHDduring tapering or cessation of immunosuppressive
drugs become again sensitive to the treatment with steroids.y
Pre- and Post-Cryopreservation Mean Values (Pre-, Post-)
Percent
Viability (%)
Relative Change
in CFU/kg (%)
Relative Change
in BFU/kg (%)
Relative Change in
Percent Viability (%)
91, 91 -30.7 -40.8 0
95.8, 85.1 -12.9 -42.7 -11.2
94.8, 84 -13 -47 -11.4
97.2, 92 -70 -61 -5
. (2) Samples processed at the San Diego Blood Bank, San Diego, CA
